Drug Trial Radar · NCT04763759
Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Feb 8, 2021
Primary completion
Mar 13, 2024
Study completion Mar 13, 2024
Sponsor
- Lead sponsor
- Trellis Bioscience LLCIndustry
- Sponsor type
- Industry
- Collaborators
- University of California, Los Angeles; Biomedical Advanced Research and Development Authority; Wellcome Trust; Sinai Hospital of Baltimore; Gulfcoast Research Institute; Phoenix Clinical Research; University of Florida; University of Alabama at Birmingham; The Methodist Hospital Research Institute; University of Virginia; University of Southern California
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.
Conditions
- Prosthetic Joint Infection
Interventions
TRL1068, a human monoclonal antibodyDrug
A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Abnormal Physical Examination FindingsTime frame: 16 weeks
- Incidence of Abnormal Serum Chemistries and HematologyTime frame: 16 weeks
- Incidence of Abnormal Vital Signs (Temperature)Time frame: 16 weeks
- Incidence of Abnormal Vital Signs (Blood Pressure)Time frame: 16 weeks
- Incidence of Abnormal Vital Signs (Heart Rate)Time frame: 16 weeks
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 24 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
USC
Los Angeles, California
UCLA
Santa Monica, California
University of Florida
Gainesville, Florida
Gulfcoast Research Institute
Sarasota, Florida
Phoenix Clinical Research
Tamarac, Florida
Sinai Hospital of Baltimore
Baltimore, Maryland
Houston Methodist Research Institute
Houston, Texas
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.